Pan Cancer T

Foundation date

09.09.2020

Sector

#Biotechnology - Therapeutics

Subsector

Pan Cancer T is a biotech spin-out that builds further on 20 years of pioneering in adoptive cell therapy developed in the laboratories of Erasmus MC. We intend to lead the fight against solid cancers through T cell receptor (TCR) gene engineered T-cell therapy. Especially, those solid cancers for which there are limited treatment options and a poor prognosis.

Upcoming events

Latest news

  • Jyseleca®▼ (Filgotinib) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in Great Britain

    16 hours ago

  • The new Walloon company Cellaïon makes its first closing

    16 hours ago

  • 7 (re)new(ed) strategic partnerships push flanders.bio forward into 2022

    11 hours ago